Depo-Provera Alternatives After Diagnosis

Discontinuing Depo-Provera After Diagnosis

The updated FDA label (December 2025) instructs healthcare providers to "discontinue Depo-Provera CI if a meningioma is diagnosed." Stopping MPA exposure removes the hormonal stimulus that drives meningioma growth through progesterone receptor activation. Some patients have experienced tumor stabilization or even shrinkage after discontinuing progestin medications.

Safer Contraceptive Options

Copper IUD (Paragard) — hormone-free, highly effective, 10-year duration. Barrier methods (condoms, diaphragm) — no hormonal exposure. Tubal ligation / vasectomy — permanent options. Non-progestin hormonal options should be discussed carefully with your doctor given the progesterone receptor mechanism.

What About Other Progestins?

The EMA review noted that the meningioma risk is primarily associated with high-dose and depot (injected) MPA. Low-dose progestin contraceptives (hormonal IUDs like Mirena, progestin-only pills) have not shown the same magnitude of risk. However, given the progesterone receptor mechanism, women diagnosed with meningioma should discuss all hormonal contraception with their doctor.

Ongoing Monitoring

After a meningioma diagnosis, regular MRI monitoring is standard of care — typically every 6–12 months initially, then annually. If you discontinue Depo-Provera and the tumor remains stable, your neurologist may extend monitoring intervals. Document all monitoring visits and results for your legal case.